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Abstract 
Analytical methods were developed for the identification of major degradation 
products of Ketoconazole, an antifungal  agent.  The stressed degradation of 
Ketoconazole drug substance was performed under acid, base, thermal, photo 
and oxidative stress conditions. The major degradation was observed under 
acid, base and oxidative stress conditions. The degradation study was 
performed on Inertsil ODS-3V, length 100 X diameter 4.6 mm, particle size 
3 μm column using gradient method. These degradants were identified by 
LC-MS technique. 
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Introduction 
Ketoconazole is an antifungal drug approved by the US FDA in 1981. Only a few analytical 
methods for the determination of the drug in biological samples and in the presence of 
other drugs have been reported [1–12]. The photodegradation behavior of Ketoconazole 
has been reported by Staub et al [13]. The drug substance is official in Ph. Eur. but the 
specified impurities are not mentioned. The present study deals with understanding the 
degradation behavior of Ketoconazole by subjecting it to acid, base, aqueous, thermal, 
photo and oxidative stress conditions. Furthermore, the two major degradation impurities 
observed under stressed condition were  identified by LC-MS techniques, elemental 
analysis, NMR, and their structures were justified through mechanistic explanation.  818  R. A. Mhaske and S. Sahasrabudhe:   
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Experimental 
Material and reagents 
Ketoconazole  drug substance was obtained from Sharon Biomedichem (Navi Mumbai, 
India). All the chemicals and reagents, hydrochloric acid, sodium hydroxide, hydrogen 
peroxide (30 %), tetrabutylammonium hydrogen sulphate, acetonitrile and methanol were 
used of analytical grade, while a millipore milli Q plus water purification system (Milford, 
USA) was used to prepare distilled water (>18 μΩ).  
Instruments  
Integrated HPLC system, Ultimate 3000 manufactured by Dionex (Germany) was used for 
method development and method validation. This system consisted  of a quaternary 
gradient pump, auto sampler, column oven and a photodiode array detector. PC installed 
Chromeleon software was used to record and to  integrate the chromatograms. The 
analysis was carried out at ambient temperature. LCMS system, Agilent ion trap 6310 was 
used for mass fragmentation analysis. NMR experiments were recorded on Bruker 500 Mz 
spectrometer. Photostability studies were performed in a photostability chamber  from 
Thermolab (India).  
Chromatographic conditions  
Analytical HPLC conditions 
Inertsil ODS (Length: 100 mm, Diameter: 4.6 mm, Particle size: 3 μm) analytical column 
was used as a stationary phase. The flow rate was 2.0 ml min
−1 and the detector was set 
at 220 nm. The volume of the sample solution injected was 10 μl. The gradient mobile 
phase consisted of Mobile phase A {(Acetonitrile: 3.4 g/l solution of tetrabutylammonium 
hydrogen sulphate (5:95 V/V)}: and Mobile phase B {(Acetonitrile: 3.4 g/l solution of tetra-
butylammonium hydrogen sulphate (50:50 V/V)}. A membrane filter of 0.45 μm porosity 
was used to filter and degas the mobile phase. (Gradient program as mentioned in Tab. 1). 
Tab. 1.  Mobile Phase gradient for HPLC chromatographic method 
Time (min)  Mobile phase A (% V/V)  Mobile phase B (& V/V) 
0  100  0 
10  0  100 
15  0  100 
17  100  0 
20  100  0 
 
Analytical LC–MS conditions 
Inertsil ODS (Length: 100 mm, Diameter: 4.6 mm, Particle size: 3 μm) analytical column 
was used as a stationary phase. The flow rate was 2.0 ml min
−1 and the detector was set 
at 220 nm. The volume of the sample solution injected was 10 μL. The gradient mobile 
phase consisted of Mobile phase A (Water)  and Mobile phase B (Acetonitrile). A 
membrane filter of 0.45 μm porosity was used to filter and degas the mobile phase. The 
gradient program as mentioned in Table  2.  The LC-Mass condition was  set using 
Nebulizer 50 PSI, dry gas temperature 350 degree and source ESI positive.   Identification of Major Degradation Products of Ketoconazole  819 
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Tab. 2.  Mobile Phase gradient for LC-MS method 
Time (min)  Water (% V/V)  Acetonitrile (% V/V) 
0  100  0 
20  0  100 
30  0  100 
 
Stress degradation of drug substance 
Stress studies were carried out under acid, base, thermal, photo and oxidative stress 
conditions. 
Acid Hydrolysis 
250.0 mg of test sample + 2ml 1N HCl into 25 ml volumetric flask. Sample heated on 
boiling water bath at 100 deg, withdrawn at 2 min and 8 min, respectively, then neutralized 
with 1N NaOH solution and make up the volume to 25 ml with methanol. Pipette out 4 ml 
into 50 ml volumetric flask and dilute to volume with methanol.  
One unknown degradation impurity was observed under acidic condition (Table  3 and 
figure 1c). In figure 1c, the main degradation product is unknown impurity at RRT 0.80.  
Tab. 3.  Results of Acid degradation (1M HCl) 
Name of  
compounds 
RRT  Sample  
“as such” 








Unknown   ~0.66  ND  ND  0.052  ND  0.085 
Unknown   ~0.72  ND  ND  0.105  0.042  0.080 
Unknown   ~0.76  ND  ND  ND  0.036  ND 
Unknown   ~0.80  0.005  0.018  0.878  5.778  22.122 
Ketoconazole  ~1.00  99.535  99.510  98.213  91.417  69.620 
Unknown   ~1.03  0.049  0.054  0.050  0.085  0.046 
Unknown   ~1.09  ND  ND  ND  0.045  ND 
Unknown   ~1.11  ND  ND  0.017  0.046  0.085 
Unknown   ~1.19  0.196  0.200  0.206  0.220  0.110 
Unknown   ~1.32  0.104  0.102  0.009  0.139  ND 
Unknown   ~1.38  0.114  0.110  0.106  0.126  ND 
 
Base Hydrolysis 
250.0 mg of test sample + 2ml 1N NaOH into 25 ml volumetric flask. Sample heated on 
boiling water bath for 10 min and 30 min,  respectively,  then neutralized with 1N HCl 
solution and make up the volume to 25 ml with methanol. Pipette out 4 ml into 50 ml 
volumetric flask and dilute to volume with methanol. 820  R. A. Mhaske and S. Sahasrabudhe:   
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One unknown degradation impurity was observed under basic condition which is the same 
as observed under acidic condition (Table 4  and  figure 1d). In figure 1d, the main 
degradation product is unknown impurity at 0.80.  
Tab. 4.  Results of Base degradation (1M NaOH) 
Name of  
compounds 
RRT  Sample 
“as such” 








Unknown   ~0.66  ND  0.083  0.124  0.088  ND 
Unknown   ~0.72  ND  0.091  0.137  0.090  0.023 
Unknown   ~0.80  0.005  0.010  0.439  5.328  10.702 
Ketoconazole  ~1.00  99.535  99.310  98.055  92.172  88.821 
Unknown   ~1.03  0.049  0.076  0.136  0.079  0.109 
Unknown   ~1.09  ND  ND  ND  ND  ND 
Unknown   ~1.11  ND  0.014  0.004  0.161  0.163 
Unknown   ~1.19  0.196  0.200  0.212  0.100  0.037 
Unknown   ~1.32  0.104  0.099  0.114  0.094  0.130 
Unknown   ~1.38  0.114  0.111  0.120  ND  ND 
 
Oxidation  
250.0 mg of test sample + 2ml 30%H2O2 into 25 ml volumetric flask and heated for 10 min 
on boiling water bath. Make up the volume to 25 ml with methanol. Pipette out 4 ml into 50 
ml volumetric flask and dilute to volume with methanol. 
One unknown degradation impurity was observed under oxidative stress condition and it is 
different from the impurity observed under acidic/ basic condition (Table 5 and figure 1e). 
In figure 1.e, the main degradation product is unknown impurity at RRT 0.72.  
Tab. 5.  Results of Oxidative degradation (30% H2O2) 
Name of 
compounds 
RRT  Sample  
“as such” 





Unknown   ~0.54  ND  ND  ND  0.219 
Unknown  ~0.56  ND  ND  ND  0.134 
Unknown   ~0.66  ND  0.125  0.149  0.084 
Unknown   ~0.72  ND  0.172  0.860  23.528 
Unknown   ~0.80  0.005  0.007  0.008  0.078 
Ketoconazole  ~1.00  99.535  99.185  98.478  74.995 
Unknown   ~1.03  0.049  0.124  0.116  0.500 
Unknown   ~1.19  0.196  0.213  0.212  0.174 
Unknown   ~1.32  0.104  0.012  0.010  0.047 
Unknown   ~1.38  0.114  0.124  0.124  0.122 
 
   Identification of Major Degradation Products of Ketoconazole  821 
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1a. Blank solution 
 
1b. Sample solution (As such) 
Fig. 1.  HPLC Chromatograms for Stressed conditions  
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1c. Stressed Acid hydrolysis 
 
1d. Stressed Alkaline hydrolysis 
Fig. 1.  (Cont.) 
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1e. Stressed Peroxide oxidation 
 
1f. Stressed Photolytic degradation 
Fig. 1.  (Cont.) 824  R. A. Mhaske and S. Sahasrabudhe:   
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1g. Stressed Thermal degradation 
Fig. 1.  (Cont.) 
Thermal 
Test sample of Ketoconazole was subjected to thermal degradation by exposure to oven 
at 105°C for 24h and 60°C at 5 days and 10 days. 250.0 mg test sample of Ketoconazole 
were dissolved and diluted with methanol to 25 ml. Pipette out 4 ml into 50 ml volumetric 
flask and dilute to volume with methanol. 
Photolysis 
About 250.0 mg test sample of Ketoconazole is kept for UV degradation for 24hours at 254 
nm wavelength and then dissolved and diluted with methanol to 25 ml. Pipette out 4 ml 
into 50 ml volumetric flask and dilute to volume with methanol. The drug substance was 
found stable under photo and thermal stress conditions as shown in below (Table 6, figure 
1f and 1g).  
Tab. 6.  Results of Thermal and UV degradation  
Name of  
compound 
RRT  Sample 
“as such” 






24 hours at 
254 nm 
Unknown   ~0.80  0.005  0.008  0.008  0.007  0.007 
Ketoconazole  ~1.00  99.535  99.576  99.578  99.561  99.536 
Unknown   ~1.03  0.049  0.046  0.050  0.055  0.053 
Unknown   ~1.19  0.196  0.179  0.183  0.190  0.195 
Unknown   ~1.32  0.104  0.103  0.093  0.102  0.097 
Unknown   ~1.38  0.114  0.085  0.084  0.083  0.109 
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2a. Chromatogram for resolution 
 
2b. Chromatogram for Oxidative degradent 
Fig. 2.  HPLC Chromatograms for preparation Oxidative degradent 
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3a. LC-Mass spectrum for Ketoconazole 
Fig. 3.  LC-Mass spectrum for Ketoconazole and degradent products 
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3b. LC-Mass spectrum for Hydrolysis degradent 
Fig. 3.  (Cont.) 828  R. A. Mhaske and S. Sahasrabudhe:   
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3c. LC-Mass spectrum for Oxidative degradent 
Fig. 3.  (Cont.)   Identification of Major Degradation Products of Ketoconazole  829 
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Preparation of Impurities 
Hydrolysis degradent, Impurity D as per Ph. Eur., is synthesized in-house and identified by 
HPLC analysis,  Mass spectrometer (figure  3b) and elemental analysis (figure  6b). 
Oxidative degradent is prepared in-house by degradation of Ketoconazole with 30% 
hydrogen peroxide by heating up to evaporate to dryness at 80°C. Ketoconazole gets 
converted to its N-oxide and identified by HPLC (figure 2b), LCMS analysis (figure 3c), 



































































MW: 446.1  
4a. Mass fragmentation behavior  
of Ketoconazole 
4b. Mass fragmentation behavior  
of N-Oxide 
Fig. 4.  Mass fragmentation behavior of Ketoconazole and N-Oxide 830  R. A. Mhaske and S. Sahasrabudhe:   
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Elemental analysis  
Elemental analysis (CHNO) of Ketoconazole, Hydrolysis degradent and Oxidative 
degradent performed and results shown below Table 7 and 8.  
Tab. 7.  Results of Elemental analysis 






Element  % Calc.  % Found  % Calc.  % Found  % Calc.  % Found 
C  58.71  58.87  58.91  58.84  56.994  58.378 
H  5.27  5.38  5.32  5.35  5.115  5.254 
N  10.54  10.55  11.45  10.62  10.230  10.092 
O  12.04  12.03  9.82  10.03  14.614  14.066 
 
Tab. 8.  No of atoms present in molecule  
Element  Ketoconazole  Hydrolysis degradent  Oxidative degradent 
C  26  24  26 
H  28  26  28 
N  4  4  4 




C26H28Cl2N4O4  C24H26Cl2N4O3  C26H28Cl2N4O5 
 
NMR analysis 
NMR analysis of Ketoconazole and the oxidative degradent were performed and the 
results are shown in Table 9.  
Tab. 9.  Results of NMR analysis 
  Ketoconazole  Oxidative degradent 
1H δ (ppm)  No of protons  1H δ (ppm)  No of protons 
1 CH3 group   2.134  2.939  2.103, 1.881  3.237 
7 CH2 and  
1 CH group 
2.988–3.897  15.075  3.200–4.794  15.525 
Aromatic protons   6.777–7.660  9.757  6.826–7.841  9.796 
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5a. NMR Spectrum of Ketoconazole 
 
5b. NMR Spectrum of N-Oxide 
Fig. 5.  NMR Spectrum of Ketoconazole and N-Oxide 832  R. A. Mhaske and S. Sahasrabudhe:   
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6a. Elemental analysis for Ketoconazole 
 
6b. Elemental analysis for Hydrolysis degradent 
 
6c. Elemental analysis for Oxidative degradent 
 
6d. Elemental analysis for Oxidative degradent 
Fig. 6.  Elemental analysis for Ketoconazole and degradent products    Identification of Major Degradation Products of Ketoconazole  833 
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Results and discussion 
The degradation of Ketoconazole was performed under different stress conditions. Two 
major degradants are observed under stress degradation. One is hydrolysis product of 
Ketoconazole observed under acid/ base condition and the other one is oxidative 
degradent  observed under oxidative stress  condition. The identification of oxidative 
degradent was achieved by LC-MS, NMR and Elemental analysis. The LC-MS data shows 
the mass 547.43 amu which exactly increase in the mass 16 amu from the Ketoconazole 
drug substance having mass 531.43 amu, which indicate the formation of N-oxide. LC-MS 
spectrums and fragmentation behavior of N-Oxide are given in figure 3c and 4b. Also, the 
elemental analysis of N-oxide shows the increase in oxygen atom (figure 6d), while in the 
case of hydrolysis decrease in oxygen atom compare to Ketoconazole. The NMR analysis 
of oxidative degradent shows the shifting of protons signal from their original position in 




































Cl H  
Hydrolysis Product 
m/z = 489.39 
1-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)- 
1,3-dioxolan-4-yl]methoxy}phenyl)piperazine 
Sch. 1.  Structure of elucidated compounds 834  R. A. Mhaske and S. Sahasrabudhe:   
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Hence, the formation of the oxidative degradation product from the drug as shown below is 
only due to the N-oxide formation at the piperazine ring. The lone pair at the nitrogen of 
the piperazine ring is more prone for oxidation to form an N-oxide. However, out of two 
nitrogen atoms,  the electron pair on the nitrogen attached to the carbonyl  group  is 
participating in resonance delocalization with this group. Hence, the most possible 
N-Oxide at the nitrogen is at the one attached to the phenolic group (scheme 1).  
Similar types of N-oxide degradents have been reported in the literature [14–16]. 
Conclusions 
The Stress degradation on Ketoconazole was carried out under different acid, base, 
thermal, photo and oxidative stress conditions. The drug was found susceptible to acid, 
base and oxidative stress degradation. The unknown degradation products formed in the 
oxidative and hydrolysis stressed sample were identified using LC–MS and elemental 
analysis (CHNO). The investigations of oxidative and hydrolysis degradent will help to take 
proper care during selection of excipients in formulation, storage, packaging and handling 
of the drug product. 
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